Molecular & Cellular Toxicology

The Korean Society of Toxicogenomics and Toxicoproteomics (대한독성유전 단백체학회)
권호 표지

Polymorphism of XRCC1 Codon 399 and Prognosis of Non-Small Cell Lung Cancer Patients After Radiotherapy

  • Cho, Eun-Kyung (University of Ulsan College of Medicine, Department of Radiation Oncology) ;
  • Yoon, Sang-Min (University of Ulsan College of Medicine, Department of Radiation Oncology) ;
  • Park, Heon-Ju (Inha University College of Medicine, Department of Microbiology) ;
  • Lee, Kwan-Hee (Inha University College of Medicine, Department of Preventive Medicine) ;
  • Kim, Jin-Hee (Seoul National University College of Medicine, Department of Preventive Medicine) ;
  • Hong, Yun-Chul (Seoul National University College of Medicine, Department of Preventive Medicine)
  • Published : 2005.12.30
Download PDF
⟨ Previous Next ⟩

Abstract

To assess that the XRCC1 399Gln variant contributes to sensitivity to ionizing radiation treatment and is associated with progression-free and overall survival, one hundred and ninety-five lung cancer patients were recruited at the Asan Medical Center from 2000 to 2003. We determined the genotypes of the XRCC1 genes by PCR-RFLP. Kaplan-Meier survival curves and the log-rank test were used to analyze the effects of genotypes on survival. Hazard ratios, adjusted for age, sex, and other potential confounders, were calculated using the Cox-proportional hazard model. Patients carrying the 399Gln variant allele under radiotherapy only had a shorter progression-free and overall survival than those with the 399Arg homozygote. However, when we analyzed for the effect of the XRCC1 Arg399Gln polymorphism in the combined treatment of surgical resection and radiotherapy, we found that patients with the 399Gln variant allele had a longer progression-free and overall survival. This study shows different associations between the XRCC1 Arg399Gln polymorphism and progression-free or overall survival depending on treatment protocol in patients with NSCLC.

Keywords

References

  1. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a metaanalysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 311, 899-909 (1995). https://doi.org/10.1136/bmj.311.7010.899
  2. Bray, F., Tyczynski, J.E. & Parkin, D.M. Going up or coming down? The changing phases of the lung cancer epidemic from 1967 to 1999 in the 15 EuropeannUnion countries. Eur. J. Cancer 40, 96-125 (2004). https://doi.org/10.1016/j.ejca.2003.08.005
  3. Bae, J.M., Jung, K.W. & Won, Y.J. Estimation of cancer deaths in Korea for the upcoming years. J. Korean Med. Sci. 17, 611-615 (2002) https://doi.org/10.3346/jkms.2002.17.5.611
  4. Bergqvist, M. et al. Evaluation of radiation-induced DNA damage and DNA repair in human lung cancer cell lines with different radiosensitivity using alkaline and neutral single cell gel electrophoresis. Cancer Lett. 133, 9-18 (1998) https://doi.org/10.1016/S0304-3835(98)00178-5
  5. Peters, L.J. The ESTRO Regaud lecture. Inherent radiosensitivity of tumor and normal tissue cells as a predictor of human tumor response. Radiother. Oncol. 17, 177-190 (1990) https://doi.org/10.1016/0167-8140(90)90202-8
  6. Price, E.A. et al. Rare microsatellite polymorphisms in the DNA repair genes XRCC1, XRCC3 and XRCC5 associated with cancer in patients of varying radiosensitivity. Somat. Cell Mol. Genet. 23, 237-247 (1997) https://doi.org/10.1007/BF02674415
  7. Taverna, P. et al. Inhibition of base excision repair potentiates iododeoxyuridine-induced cytotoxicity and radiosensitization. Cancer Res. 63, 838-846 (2003)
  8. Thompson, L.H., Brookman, K.W., Jones, N.J., Allen, S.A. & Carrano, A.V. Molecular cloning of the human XRCC1 gene, which corrects defective DNA strand break repair and sister chromatid exchange. Mol. Cell Biol. 10, 6160-6171 (1990) https://doi.org/10.1128/MCB.10.12.6160
  9. Caldecott, K.W., McKeown, C.K., Tucker, J.D., Ljungquist, S. & Thompson, L.H. An interaction between the mammalian DNA repair protein XRCC1 and DNA ligase III. Mol. Cell Biol. 14, 68-76 (1994) https://doi.org/10.1128/MCB.14.1.68
  10. Gryk, M.R. et al. Mapping of the interaction interface of DNA polymerase beta with XRCC1. Structure 10, 1709-1720 (2000) https://doi.org/10.1016/S0969-2126(02)00908-5
  11. Whitehouse, C.J. et al. XRCC1 stimulates human polynucleotide kinase activity at damaged DNA termini and accelerates DNA single-strand break repair. Cell 104, 107-117 (2001) https://doi.org/10.1016/S0092-8674(01)00195-7
  12. Vidal, A.E., Boiteux, S., Hickson, I.D. & Radicella, J.P. XRCC1 coordinates the initial and late stages of DNA abasic site repair through protein-protein interactions. EMBO J. 20, 6530-6539 (2001) https://doi.org/10.1093/emboj/20.22.6530
  13. Ladiges, W., Wiley, J. & MacAuley, A. Polymorphisms in the DNA repair gene XRCC1 and age-related disease. Mech. Ageing Dev. 124, 27-32 (2003) https://doi.org/10.1016/S0047-6374(02)00166-5
  14. Beckman, K.B. & Ames, B.N. Oxidative decay of DNA. J. Biol. Chem. 272, 19633-19636 (1997) https://doi.org/10.1074/jbc.272.32.19633
  15. Taylor, R.M., Thistlethwaite, A. & Caldecott, K.W. Central role for the XRCC1 BRCT I domain in mammalian DNA single-strand break repair. Mol. Cell Biol. 22, 2556-2563 (2002) https://doi.org/10.1128/MCB.22.8.2556-2563.2002
  16. Lunn, R.M., Langlois, R.G., Hsieh, L.L., Thompson, C.L. & Bell, D.A. XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res. 59, 2557-2561 (1999)
  17. Divine, K.K. et al. The XRCC1 399 glutamine allele is a risk factor for adenocarcinoma of the lung. Mutat. Res. 461, 273-278 (2001) https://doi.org/10.1016/S0921-8777(00)00059-8
  18. Hu, J.J. et al. Amino acid substitution variants of APE1 and XRCC1 genes associated with ionizing radiation sensitivity. Carcinogenesis 22, 917-922 2001) https://doi.org/10.1093/carcin/22.6.917
  19. Zhou, W. et al. Polymorphisms in the DNA repair genes XRCC1 and ERCC2, smoking, and lung cancer risk. Cancer Epidemiol. Biomarkers Prev. 12, 359- 365 (2003)
  20. Lee, S.G. et al. Genetic polymorphisms of XRCC1 and risk of gastric cancer. Cancer Lett. 187, 53-60 (2002) https://doi.org/10.1016/S0304-3835(02)00381-6
  21. Ward, J.F. Mechanisms of DNA repair and their potential modification for radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 12, 1027-1032 (1986) https://doi.org/10.1016/0360-3016(86)90220-8
  22. Hu, J.J., Smith, T.R., Miller, M.S., Lohman, K. & Case, L.D. Genetic regulation of ionizing radiation sensitivity and breast cancer risk. Environ. Mol. Mutagen 39, 208-215 (2003) https://doi.org/10.1002/em.10058
  23. Hu, J.J., Smith, T.R., Miller, M.S., Lohman, K. & Case, L.D. Genetic regulation of ionizing radiation sensitivity and breast cancer risk. Environ. Mol. Mutagen 39, 208-215 (2003) https://doi.org/10.1002/em.10058
  24. Shen, H. et al. Polymorphisms of the DNA repairQ gene XRCC1 and risk of gastric cancer in a Chinese population. Int. J. Cancer 88, 601-606 (2000) https://doi.org/10.1002/1097-0215(20001115)88:4<601::AID-IJC13>3.0.CO;2-C
  25. Duell, E.J. et al. Polymorphisms in the DNA repair gene XRCCI and breast cancer.Cancer Epidemiol.Biomarkers Prev. 10,217-222(2001)
  26. Rosell, R. et al. Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer. Cancer Control 10, 297-305 (2003)
  27. Lambin, P. & Lawton, P. Radiosensitivity testing of normal tissues: a way to optimise radiotherapy? Eur.J. Cancer 30A, 576-577 (1994)
  28. Metzger, R. et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J. Clin. Oncol. 16, 309-316 (1998)
  29. Lord, R.V. et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res. 8, 2286-2291 (2002)